Cardiovascular diseases (CVDs) are the main cause of death worldwide representing 30% of all global deaths. Obstructive sleep apnea-hypopnea (OSAH) has been associated with several serious cardiovascular comorbidities. OSAH occurs in 17%-24% of North American adults that increase the risk of sudden cardiac deaths between 12 midnight and 6 am. OSAH is considered as an independent risk factor for CVD such as systemic hypertension (HTN), pulmonary arterial HTN, coronary artery disease, stroke, cardiac arrhythmias, heart failure, which raise both cardiovascular morbidity and mortality and the increase demand for health-care resources. Several mechanisms have been suggested to link OSAH and vascular diseases including increases in sympathetic activation, oxidative stress, inflammation, endothelial dysfunction, coagulation, and metabolic dysregulation. This review will provide insights on mechanisms by which OSAH might contribute to the pathogenesis of CVD. Continuous positive airway pressure (CPAP) is considered the gold standard in the treatment of OSAH with improved metabolic and CV endpoints. To a lesser extent, oral appliance therapy and upper airway or mandibular advancement surgery are palliative measures that leave the patient with significant residual apnea-hypopnea. There is increasing evidence that adequate CPAP therapy leads to a significant reduction in cardiovascular morbidity. Moderate-to-severe OSAH not treated with CPAP was an independent risk factor for relapse of a CVD event, and adequate CPAP treatment improved cardiovascular outcomes in elderly patients. 
introduction
Cardiovascular diseases (CVDs) are the main cause of death worldwide representing 30% of all global deaths. [1] Obstructive sleep apnea-hypopnea (OSAH) has been associated with several cardiovascular comorbidities. [2, 3] OSAH is the most common type sleep-disordered breathing and is caused by narrowing and obstruction of the upper airway. It is characterized by repetitive reduction and pauses in breathing during sleep, despite the effort to breathe and is usually associated with a reduction in blood oxygen saturation. These reduction and pauses in breathing, called "apnea-hypopnea" typically last for 20-40 s, sometimes over 1 min. Patients are categorized as having mild, moderate, or severe OSAH depending on the apnea/hypopnea index (AHI), which is the total number of apnea/hypopnea episodes per hour of sleep. At a population level, at least 4% males and 2% females are diagnosed with sleep apnea and its symptoms, and it is estimated that 1 of every 5 adults have OSAH and that 1 of every 15 adults have moderate OSAH. In females, the prevalence increases from 3% for the third decade of life to 36% in the seventh decade. In men, the prevalence for the third decade is 4% and increases to 50% during the seventh decade. [4] OSAH in much higher proportion among Asians due to a higher rate of genetically determined craniofacial features of Mallampati Class III-IV, micrognathia, and retrognathia. OSAH among Asians origin is mostly nonobese body mass index (BMI) <25 (63.4%) compared to obese (36.6%). Asians in spite of being non-obese have a higher proportion of severe OSA (AHI ≥30). [5] Obstructive Sleep Apnea-Hypopnea and Cardiovascular Diseases in Adults and Mallampati classification when analyzed individually proved to have lesser statistical significance in ordinal regression using AHI categories (age: P < 0.00001, snoring: P = 0.02, BMI: P < 0.00001, ESS: P < 0.10, and Mallampati: P = 0.007) than the multilateral ChanScore (P < 0.0000000001) which accurately diagnosed over 80% of the population's OSAH (AHI ≥5 threshold for OSAH as defined by the American Academy of Sleep Medicine. Their scoring system, ChanScore, predicts the presence and severity of OSAH at the bedside and correlated remarkably well with sleep laboratory polysomnogram results. [6] ChanScore is a simple, valuable clinical tool for physicians, or health-care workers who may have no training in sleep medicine, to quickly identify patients who may have OSAH and predict its severity [ Table 1 ].
In a large countries such as China or India with combined population of 2.3 billion with very few sleep, laboratories and very few sleep medicine physicians; ChanScore would help triage those patients with high suspicion of OSAH to be referred to sleep laboratory; thus, prioritizing constraint health-care resources [ Table 2 ].
For example, at ChanScore 5, probability of OSAH is 100%, 33.7% predictability AHI 5-14, 21.1% predictability AHI 15-29, and 19% predictability AHI = or >30. The higher the ChanScore is, the more severe is the predictability of OSAH.
Many clinical studies strongly suggest that OSAH is an independent risk factor for CVDs such as systemic hypertension (HTN), pulmonary arterial hypertension (PAH), coronary artery disease, stroke, arrhythmias, and heart failure (HF). Several mechanisms have been suggested to link OSA and vascular diseases including increases in sympathetic activation, oxidative stress, inflammation, endothelial dysfunction, coagulation, and metabolic dysregulation. [5] This review will provide insights on mechanisms by which OSAH might contribute to the pathogenesis of CVD. Continuous positive airway pressure (CPAP) and oral appliance therapy are the two treatments for OSAH whose effects on cardiovascular endpoints. There is increasing evidence that adequate CPAP therapy leads to a significant reduction in cardiovascular morbidity. However, large-scale randomized trials are needed to determine, definitively, whether treating OSAH improves cardiovascular outcomes [ Figure 1 ].
importance of obstructiVe sleep apnea in cardioVascular disease
Persons with OSAH have a 300% higher risk of heart attack, stroke, or death than those unaffected. [7] In severe and prolonged cases, increased in pulmonary pressures are transmitted to the right side of the heart. This can result in a severe form of congestive HF (CHF) known as cor pulmonale. Diastolic dysfunction often occurs early before any cardiac symptoms appear. [8, 9] Once symptoms of moderate exertion occurs, cardiac remodeling such as one or combination of the following: atrial enlargement (left atrial enlargement and right atrial enlargement), mitral valvular regurgitation, tricuspid valvulkar regurgitation, diastolic dysfunction failure, PAH, and left ventricular hypertrophy (LVH) are often irreversible and put the patient at great risk for CV events such as worsening HF, stroke, myocardial infarction, serious arrhythmias, or sudden cardiac death [ Figures 2 and 3 ].
One prospective study showed patients with OSAH, compared with healthy controls, initially had statistically significant increases in vascular endothelial growth factor (P = 0.003) and significantly lower levels of nitrite-nitrate (P = 0.008), which might be pathogenic factors in the cardiovascular complications of OSAH. [10] Studies have found that 30%-40% of hypertensive (HT) patients are positive for OSA when tested, and 50% of patients with OSAH have a history of HTN. [2] Among patients with resistant HTN, the prevalence of OSAH is especially high. [11, 12] 
Pathophysiological mechanisms of obstructive sleep apnea-induced cardiovascular diseases
The mechanisms of OSAH for initiation and aggravation of CVD have not been fully elucidated. Several pathogenic factors are proposed as intermediate mechanisms linking OSAH with CVD, mainly endothelial dysfunction, sympathetic activation, inflammation, oxidative stress, hypercoagulability, and metabolic dysregulation.
Endothelial dysfunction
The vascular endothelium is a confluent, cellular monolayer that lines the entire vascular compartment at the interface between blood and the vessel wall. The vascular endothelium is intimately involved in controlling vasomotor tone and is the main regulator of vascular homeostasis. The endothelium continuously adjusts the balance between vasoconstriction and vasodilatation. If this balance is tilted toward vasoconstriction, endothelial dysfunction occurs, causing damage to the arterial wall. There is evidence suggesting an impaired endothelial function in OSAH patients. Endothelial dysfunction occurs in response to cardiovascular risk factors and can precede or accelerate the development of atherosclerosis. [13] The assessment of endothelial function in OSA involves functional evaluation of vascular responses recording changes in blood flow in response to endothelium-dependent vasodilators or hypoxemia, quantification of levels of circulating apoptotic endothelial cells and measuring plasma concentrations of various endothelial biomarkers. [14] Several studies show indirect evidence of reduced nitric oxide availability suggesting that inflammation and vascular endothelial dysfunction contribute to the development of vascular diseases in patients with OSAH. [15] Moreover, increased sympathetic activation and oxidative stress, common in patients with OSAH, might contribute to the development of endothelial dysfunction. Increased oxidative stress reduces nitric oxide availability and increases expression of reactive oxygen species (ROS), which activates inflammatory pathways that facilitate the recruitment and accumulation of blood cells on the vasculature of the endothelial lining. Effective CPAP therapy in patients with OSAH reverses vascular endothelial dysfunction and inflammation and enhances endothelial repair capacity. [16] CPAP withdrawal has also been associated with the impaired endothelial function. [17] Therefore, evidence shows that OSAH directly affects the vascular endothelium by promoting inflammation and oxidative stress, while decreasing nitric oxide availability and repair capacity. Furthermore, CPAP treatment reverses endothelial dysfunction and enhances endothelial repair capacity.
Sympathetic activation
There is evidence that OSAH might be associated with the increased sympathetic activity. [18] The sympathetic activation is considered to be the main mechanism involved in the development of CVDs in OSAH, which is characterized by a marked sympathetic overdrive, as documented by the elevated sympathetic nerve firing rate detected in peripheral muscle nerves. OSAH affects sympathovagal modulation during sleep, and this impact has been correlated with the severity of the disease. Acute periods of hypoxia promote vasoconstriction, increased heart rate, and blood pressure (BP). OSAH is highly relevant to patients with HTN. These two conditions frequently coexist (an estimated 50% of patients with HTN have) concomitant OSAH, and recent evidence supports the notion that OSAH represents the most prevalent secondary contributor to elevated BP in patients with resistant HTN. [19] Increased activity of the sympathetic nervous system constricts blood vessels and increases cardiac output. The degree of sympathetic nervous system activation correlates with the severity of the increase in BP and is more pronounced in the context of metabolic diseases such as diabetes, obesity, and the metabolic syndrome. The measurement of sympathetic nerve activity in muscle yields accurate and direct information about sympathetic nerve impulses. Moreover, sympathetic tone can be evaluated by measurement of plasma and urinary catecholamines. Hypoxia and hypercapnia act synergistically to heighten sympathetic activity, and this effect is especially marked during the apneic event. Patients with OSAH have a high frequency of arousals from sleep, which induces a sympathetic burst during each apnea-hypopnea episode. Patients with OSAH have high sympathetic activity when awake, with further increases in BP and sympathetic activity during sleep. Several randomized trials have shown that CPAP treatment reduces sympathetic nervous system activity and attenuates the increased sympathetic tone in patients with OSAH. [20] 
Inflammation
Hypoxemia appears to be an important mechanism for triggering inflammatory pathways. OSAH seems to be associated with local and systemic inflammation. Local inflammatory changes could be partly due to snoring, which triggers vibration frequencies associated with soft-tissue damage. Histological analysis of tissues from patients with OSAH undergoing uvulopalatopharyngoplasty shows substantial subepithelial edema, plasma inflammatory molecules, and cells increase such as plasma cytokines (interleukin [IL]-6, IL-6, IL-8, tumor necrosis factor-a [TNF-a]), intercellular adhesion molecules (ICAM-1) and selectins (E-selectin), C-reactive protein, and serum amyloid-A. [21] [22] [23] infiltration, and reduction in the surface area of connective tissue papillae, which provide anchorage for the epithelium. Polymorphonuclear leukocytes are also increased in nasal lavage fluid of patients with OSAH, compared with people without OSAH. [24] In addition to local inflammation, systemic inflammation is seen in patients with OSAH. Chronic inflammation has been closely related to the formation and progression of atherosclerosis. In patients with OSAH, activation of redox-sensitive gene expression is suggested by an increase in specific protein products, including inflammatory cytokines. This implies the participation of redox-sensitive transcription factors, such as hypoxia-inducible factor-1, activator protein-1, and nuclear factor κB (NF-κB). NF-κB is one of the key regulators of inflammation, immune response, and cell survival. A non-randomized study suggested that NF-κB is highly activated in patients with OSAH compared with healthy controls and that CPAP treatment reduces NF-κB activation. Gene set enrichment analysis identified a number of gene sets up-regulated in adipose tissue of OSAH patients, including the pro-inflammatory NF-κB pathway and the proteolytic ubiquitin/proteasome module. [25, 26] Several studies of patients with OSAH have reported raised plasma concentrations of other inflammatory markers, such as cytokines (including IL-6 and TNF-α), matrix metalloproteinases, and acute phase proteins, as well as endothelial adhesion molecules, such as ICAM-1 and vascular cell adhesion molecules. [27] Furthermore, adipokines are involved in a range of processes, including immunity and inflammation, and several studies have shown that patients with OSAH have higher concentrations of proinflammatory adipokines than patients without OSAH. [28] These proinflammatory adipokines seem to contribute substantially to the inflammatory state of obese patients. Obesity is the most common comorbidity and is present in more than half of the patients with OSAH. Obesity is considered a chronic inflammatory situation in itself; therefore, it might be the most important confounding factor in the association between OSAH and inflammation. Increased serum TNF-α, ICAM-1, and TNF-α expression in adipose tissue provide a mechanistic basis for enhanced inflammation in patients with OSAH. [29] Oxidative stress Oxidative stress arises from an imbalance in redox status between the production and removal of ROS. Although free radicals have important roles in regulating signal transduction and cellular function, their overproduction can react with and cause damage to lipids, proteins, and DNA, which is the pathogenic basis of age-related and chronic diseases such as cancer, CVD, diabetes, chronic inflammation, and neurodegenerative disorders. Recent studies show important links between hypoxia-related and ROS-related oxidative stress and CVD in OSAH patients. [30, 31] Mitochondria are major sources of superoxide anion due to reactions occurring during oxidative phosphorylation. It is estimated that 3%-5% of the oxygen consumed by mitochondria is converted to superoxide anion during aerobic respiration. During hypoxia, ROS production is elevated due to excessive mitochondrial reduction. [32] A randomized trial showed that patients with OSAH had significantly higher isoprostane and lower nitric oxide concentrations than healthy individuals and that these were normalized by CPAP therapy. [33] In addition to an increase in ROS production, some researchers have suggested that OSAH might enhance oxidative stress by reducing the antioxidant capacity of blood. [34] The degree of oxidative stress in patients with OSAH varies and is uncommon in patients with no comorbidities. Furthermore, sex-related differences in susceptibility to oxidative stress have been noted; in oxidative brain injuries experimentally induced in mice, premenopausal females had greater protection than age-matched males or ovariectomized age-matched females. [35] This sex-related susceptibility could be related to differences in cardiovascular morbidity associated with OSAH. Evaluating oxidative damage in OSAH patients is essential, and many studies confirm the association of OSAH with oxidative stress through measurements of oxidative stress markers. Antioxidant capacity is impaired in OSAH patients. Christou et al. showed a linear negative relationship between antioxidant capacity and AHI. [36] Total antioxidant status in OSAH patients is significantly decreased (1.4 mmol/L) when compared to healthy controls (1.5 mmol/L, P = 0.0001), with lower levels of Vitamin A (64 µg/dL) and vitamin E (1525 µg/dL) when compared to control (74 and1774 µg/dL, resp.). [37] 
Hypercoagulability
There is evidence of a hypercoagulability status in patients with OSA, which might contribute to increased morbidity and mortality in OSAH, [38, 39] particularly strokes [40] and myocardial infarction. [41] Patients with OSAH show a morning increase in plasma fibrinogen concentration and whole blood viscosity, as well as low-fibrinolytic activity. Furthermore, studies have shown high levels of coagulation factors XIIa, VIIa, and thrombin-antithrombin complex. [42] Patients with OSAH show increased platelet activation and aggregation, although the mechanisms of platelet activation are not completely understood and might be related to increased sympathetic activity. Hypoxemia and repetitive arousals from sleep combine to produce raised concentrations of epinephrine and norepinephrine, and high numbers of circulating catecholamines cause concentration-dependent platelet activation in vitro and in vivo. [43] Interventional studies have shown that CPAP treatment reduces coagulability and the risk of thrombosis in patients with OSAH, although not all coagulability markers were reduced after CPAP treatment. [44, 45] 
Metabolic disorders
OSAH and obesity commonly coexist and share multiple pathophysiological mechanisms and complications including glucose metabolism disturbance, dyslipidemia, and systemic inflammation, [46] [47] [48] which together result in increased cardiovascular risk.
Although experimental evidence and emerging data in humans indicate an association between OSAH and dyslipidemia, this relationship remains controversial, requiring more studies for full elucidation. [49, 50] Metabolic syndrome is common in patients with OSAH, and OSAH is frequently found in conditions associated with metabolic abnormalities. Studies show that patients with OSAH have higher free fatty acid concentrations than controls, and this could be one of the mechanisms involved in the metabolic complications of OSAH. [51] Insulin resistance is a known risk factor that may contribute to coronary artery disease (CAD) in OSAH. Several studies have postulated that OSAH represents a stress which promotes insulin resistance, independently of BMI, which is implicating to atherogenesis. Independent of adiposity, OSAH is associated with impairments in insulin sensitivity, glucose effectiveness, pancreatic B-cell function, and dyslipidemia. [52] There is much debate about whether OSAH increases the risk of Type 2 diabetes, and whether CPAP treatment could reverse insulin resistance. [53, 54] Some clinical trials have shown a partial benefit of CPAP treatment for metabolic components. Sharma et al. reported that 3 months of CPAP therapy partially reversed metabolic abnormalities. [55] Weinstock showed that insulin-glucose tolerance was not normalized after CPAP in patients with OSAH and obesity. [56] The sleep AHEAD study (Action for Health in Diabetes) revealed a high prevalence of OSAH in obese diabetic patients (87% of analyzed subjects).
[57] The sleep heart health study showed that hypoxemia-related sleep disorder was an independent factor for the development of insulin resistance and glucose intolerance in the studied population. [58] A recent meta-analysis evaluated six prospective cohort studies that followed for 2.7-16 years a total of 5953 patients. During follow-up, 332 new cases of diabetes occurred, mainly in patients with moderate-to-severe OSAH (relative risk 1.63, 95% confidence interval [CI] = 1.09-2.45). [59] Obstructive sleep apnea and cardiovascular events and mortality Evidence from population-based and clinical cohorts suggests that severe OSAH might be associated with increased deathparticularly cardiovascular death. Marin et al. demonstrated that male patients with untreated severe OSAH have significantly increased risk of fatal (odds ratio [OR] 2.87, 95% CI = 1.17-7.51, P = 0.025) and nonfatal (3.17, 1.12-7.51, P < 0.001) cardiovascular events compared with healthy participants. [60] Two population-based cohorts, the Wisconsin Sleep Cohort and the Sleep Heart Health Study (SHHS), prospectively followed up 1522 participants for 18 years and 6441 individuals for 8·2 years, respectively. In both cohorts, and compared with non-OSAH participants, severe OSAH was independently associated with increased all-cause and cardiovascular mortality. [61, 62] Mild-to-moderate OSAH was not associated with increased mortality. [63] Yaggi et al. showed that patients with an AHI >5 had a two-time increase in the adjusted risk of stroke or death compared with non-OSAH participants, and the risk of development of the composite endpoint increased in a dose-response manner with increasing severity of OSAH. [64] Even in patients without previous CVD, the presence of OSAH was an independent predictor of cardiovascular mortality. Gami et al. showed that AHI was correlated with the risk of sudden death from cardiac causes from midnight to 6 am. [65] CPAP treatment has been associated with reduced mortality in observational studies. It has been reported that men with untreated, severe OSAH had a nearly 3-times increase in cardiovascular mortality, whereas those with similar OSAH severity who received CPAP treatment showed a risk of fatal events similar to that of non-OSAH participants while mild-to-moderate OSAH was not linked with mortality. [60] Some observational studies have found a similar protective effect of CPAP on cardiovascular mortality. Available evidence suggests that severe OSAH is linked with greater cardiovascular risk, including death, whether milder forms of the disorder also predict cardiovascular outcomes remains unclear. Chan et al. have demonstrated that severe OSAH correlates with a high risk of arrhythmic death. Therefore, to properly address the effect of CPAP in reducing the cardiovascular risk, including acute coronary syndrome and stroke, prospective multicenter, randomized studies are needed. Ongoing large, multicenter randomized trials will hopefully shed some light on these issues.
Obstructive sleep apnea and coronary heart disease
The prevalence of OSAH in patients with coronary heart disease is about two times higher than in the general population, and up to 70% of patients admitted for acute coronary heart disease have undiagnosed OSAH. Several studies have shown an association between chronic CAD and OSAH, [66, 67] particularly when both diseases are severe. [68] An increased prevalence of OSAH was also described in patients with the acute coronary syndrome, including predicting worse cardiovascular outcomes. [69, 70] Consistent with the above observations, an extensive literature review conducted by Phillips et al. 83 concluded that there is evidence of an important correlation between atherosclerotic disease and OSAH that is directly proportional to the severity of both disease processes. Coronary artery calcifications, a marker of subclinical coronary disease, were present in 67% of patients with OSAH versus 31% of those without OSAH. [68] OSAH has also been implicated as a risk factor for nocturnal ischemic events. Kuniyoshi et al. reported that myocardial infarction occurred between 12 am and 6 am in 32% of patients with OSAH, versus 7% of patients without OSAH. [71] Peker et al. prospectively followed up 308 snorers with no previous heart disease for 7 years. The presence of OSAH versus no OSAH was associated with an increased adjusted relative risk for the development of coronary heart disease of 4.6 (95% CI 1.8-11.6; P = 0·001). [72] Yumino et al. reported that OSAH is an independent predictor of a worse outcome after percutaneous coronary intervention in patients with acute coronary heart disease. [73] However, epidemiological studies did not find a clear association between OSAH and coronary heart disease after adjustment for confounders. [67] Obstructive sleep apnea and arrhythmias Cardiac rhythm disorders have been described in patients with OSA, the most common types being atrial fibrillation (AF), unsustained ventricular arrhythmias, sinus arrest, and second-degree atrioventricular conduction block. [74, 75] Over 50% of patients with OSAH have nocturnal arrhythmias that increase in frequency in relation to increases in AHI and severity of hypoxemia. [76] Cardiac rhythm disorders are associated with increased risk of sudden death during sleep. [65] Although studies continue to attempt to determine the true influence of OSAH on the development of arrhythmias, it is unknown whether OSAH acts as a triggering factor, or arrhythmias arise from the high number of comorbidities common in OSAH patients. The SHHS suggested that patients with OSAH had increased likelihoods of AF, non-sustained tachycardia, and complex ventricular ectopy. [77] Bradyarrhythmias can be provoked by cardiac vagal activation caused by apnea-related hypoxemia in otherwise structurally normal hearts. Although one study showed that arrhythmias were 18 times more likely to occur after an apneic event than after normal breathing, the prevalence and clinical relevance of cardiac arrhythmias in patients with OSAH are still unknown. [78] Mehra et al. reported that individuals with severe OSAH were 4 times more likely than those without OSAH (AHI <5) to have AF. [75] Cadby et al. recently reported their study including 6841 cases aged (48.3 ± 12.5 years), male (77%). Among them, 455 cases developed AF during a median 11.9 years' follow-up. They conclude that OSAH diagnosis and severity are independently associated with incident AF. [78] A decrease in nocturnal oxygen saturation has been identified as a predictor of incident AF, independent of obesity. [79] Untreated OSAH versus treated OSA has also been associated with a higher recurrence of AF after cardioversion and a higher risk of ablation failure. [80] Chan et al. postulated the mechanism of sudden cardiac death in OSAH. Repetitive hypoxemia arousals lead to hyperadrenergic state, temporal dispersion of reentrant arrhythmias in the ventricle triggering ventricular fibrillation. The more severe the OSAH, the higher is the risk of arrhythmias [ Figure 4 ].
Obstructive sleep apnea and heart failure OSAH might induce or worsen HF through several mechanisms. Hypoxemia is an independent predictor of impaired ventricular relaxation and myocardial contractility. Repetitive and acute reductions in intrathoracic pressure cause an increase in the left ventricular afterload and a decrease in the left ventricular preload, accompanied by reductions in stroke volume. OSAH is present in 10%-35% of patients with HF, [81] [86] Several studies describe the prevalence of OSAH in HF patients ranging from 12% to 53%. However, the results of these studies should be interpreted with caution because of referral bias. [87, 88] Hall et al. found that in patients with HF with reduced ejection fraction and OSAH, short-term CPAP increased hydroxyephedrine retention, indicating improved myocardial sympathetic nerve function, but overall did not affect energetics. In those with more severe OSAH, CPAP may improve cardiac efficiency. Further outcome-based investigation of the consequences of CPAP is warranted. [89] In randomized controlled studies in HF patients with OSAH, CPAP treatment for few weeks increased cardiac function, decreased BP and sympathetic activity. [90, 91] However, the long-term benefit of CPAP therapy on these patients needs further investigation. Another important study concerning cardiac functional and structural changes in OSAH evaluated severe OSAH patients by echocardiography [ Figure 5 ]. These patients were obese, had symptoms of daytime sleepiness, had no known cardiac or obstructive pulmonary disease, had daytime HT, and had an increased resting HR. The structural and functional cardiac alterations with right ventricular dilatation, LVH, and reduced function of both were significantly improved after 6 months of CPAP treatment. [92] Studies in both children and adults have found an association between OSAH and asymptomatic, early cardiac remodeling, which suggests that OSAH is associated with altered cardiac structure and function. [93] There is some controversy as to whether OSAH increases mortality in patients with HF. Robinson et al. followed up 78 patients with HF and very reduced LVEF for 52 months and found a similar prevalence of OSAH in survivors and nonsurvivors. [94] However, in two observational studies, OSAH was independently associated with mortality in ischemic or non-ischemic HF. [95, 96] The effect of OSAH treatment on clinical outcomes, beyond physiological improvements, remains to be established.
Chan et al. reported a case study of a 66-year-old man with severe end-stage HF, AF, that was refractory to pharmacotherapies, was given "4 months to live" by his cardiologist. Polysomnograms revealed severe OSAH, central sleep apnea (CSA) that failed on CPAP. The patient was then switched to bi-level positive airway pressure (BiPAP) with 02 bleeds into the BiPAP combined with standard HF pharmacotherapies. Within 18 months of treatments of cardiac and sleep disorders; his HF was normalized and reversal of AF [ Figures 6 and 7] . [97] Polysomnogram showed severe OSAH, AHI 55. The patient failed CPAP was placed non-BiPAP with bleed in 02 combined with standard HF pharmacotherapies.
Obstructive sleep apnea-hypopnea and hypertension
Hypertension is a common feature of patients with OSAH. These two conditions were frequently concomitant. It is estimated that a third of HT patients have OSAH, and about half of the patients with OSAH are HT. [2] OSHA is included elevation of BP, which contributes to the left ventricular dysfunction and especially LVH. [82] Furthermore, nocturnal hypoxia is an independent risk factor for impaired left ventricular relaxation, promoting ventricular wall stress and enlargement of this cavity, and poorer prognosis. [83] Whether these effects of OSAH can cause HF has yet to be established, but they might worsen a pre-existing HF. OSAH acutely affects cardiac function. Studies have shown that the impairment of LV diastolic function is common in OSAH patients, suggesting a subclinical myocardial disease that may account for the risk of HF. [84] Recently, a large prospective cohort study evaluates the effect of OSAH on postdischarge mortality in patients with acute HF (AHF). They found that newly diagnosed OSAH during AHF hospitalization are independently associated with post-discharge mortality. [85] Cross-sectional data from the SHHS have shown a strong association of sleep-disordered and treatment of high BP. [98] OSAH is present in about 80% of patients with resistant HTN and is the leading recognizable cause of HTN in about two-thirds of these patients. [11] One recent prospective longitudinal cohort study (1889 participants, 12.2 years of median follow-up) identified an increased hazard ratio for incident HTN in patients with OSAH compared with controls. The OSA-HTN association remained independent of confounders including age and obesity. Follow-up of this patient cohort revealed a dose-response relationship between the severity of OSAH and the cumulative incidence of HTN implicating OSAH as a factor in the development of HTN. [99] The sympathetic activation associated with obstructive events during sleep might blunt nocturnal lowering of BP and result in a higher occurrence of a non-dipping pattern in patients with OSAH. In patients with resistant HTN, other pathogenic pathways might also be involved. Plasma aldosterone concentration is positively associated with the AHI in these patients, and OSAH severity has been reported as being worse in patients with hyperaldosteronism. One explanation for these findings is that the fluid retention associated with hyperaldosteronism exacerbates OSAH by increasing the movement of fluids to the surrounding tissues, particularly in the neck; this might contribute to the increased propensity for airway collapse during sleep. This hypothesis is supported by a study assessing rostral fluid shifts in patients with OSAH and resistant HTN, which showed that the severity of OSHA is strongly related to the amount of fluid displaced from the legs overnight. [100, 101] Results from prospective longitudinal studies suggest that moderate-to-severe OSAH is an independent risk factor for HTN and for development of a non-dipping BP pattern. [102, 103] Two population-based studies have reported conflicting data suggesting that the association between OSAH and HTN might not be as strong as was once thought. [104] Effects of obstructive sleep apnea-hypopnea treatment on hypertension A possible preventive role of CPAP in reducing incident HTN was suggested by the large prospective Zaragoza Sleep Cohort study, which reported a lower incidence of newly diagnosed HTN in those patients with OSAH who tolerated CPAP. [99] Several meta-analyses have reported that CPAP treatment significantly decreases BP by about 2 mm Hg and that CPAP compliance and higher baseline BP are predictors of successful BP reduction. [105, 106] Durán-Cantolla et al. did a study of 340 patients with recently diagnosed, untreated HTN and moderate-to-severe OSAH, who were randomly assigned to CPAP or sham CPAP and followed up for 3 months. BP was measured by 24-h ambulatory BP monitoring (ABPM). The CPAP group showed a significant decrease in mean ABPM of 1.5 mm Hg. [107] In a multicenter, randomized trial involving 359 HT patients with OSAH who were randomly assigned to CPAP or conservative treatment for 1 year, results showed that CPAP compliance of >5.6 h per night was associated with a reduction in BP of about 3.5 mm Hg. [108] Obstructive sleep apnea-hypopnea and stroke
The prevalence of OSAH is higher in stroke patients than in the general population, ranging from 50%-70%. [109] Evidence from a variety of studies have suggested a link between stroke and OSAH and demonstrated a high prevalence of OSAH in patients with stroke. [110, 111] Similarly, patients with recurrent strokes had a higher prevalence of OSAH than those with 1 st -time strokes (74% vs. 57%). [109] Vascular injury to the respiratory and upper-airway muscles brain centers can precipitate central or obstructive events. Longitudinal, population-based studies suggest that OSAH can be a risk factor for stroke. Data from the SHHS87 showed that OSAH significantly increased (3 times) the incidence of ischemic stroke in men, and this association was confirmed in elderly patients. [112] In clinical cohorts, Valham et al. found that OSAH was independently associated with an increased risk of stroke in 392 patients with coronary heart disease who were followed up for 10 years. [113] Sahlin et al. prospectively followed up 132 patients with stroke and showed that the risk of death was higher among patients with moderate-to-severe OSAH. [114] A recent meta-analysis shows that each 10-unit increase in the AHI is associated with a relative increase of 36% in the odds of having a cerebrovascular event. [115] Intermittent hypoxia is probably the most critical factor in the cerebrovascular abnormalities predisposing OSAH patients to stroke. Additional, impaired cerebrovascular response to hypoxia has been reported in OSAH patients, which is consistent with underlying abnormal endothelial function. Hence, fluctuations in BP, reduction in cerebral blood flow, altered cerebral autoregulation, endothelial dysfunction, accelerated atherogenesis, pro-thrombotic, and pro-inflammatory states are also some of the mechanisms which have been implicated in increased risk of stroke in OSAH patients. [2] Data from observational studies report that treatment of OSAH is associated with a decreased risk of cardiovascular and cerebrovascular events. [60, 82] OSAH may contribute to the development of stroke in OSAH patients and once stroke has occurred poor outcome for these patients has been reported. [110] Redline et al. followed a total of 5422 participants without a history of stroke at the baseline examination and untreated for OSAH for a median of 8.7 years. A significant positive association between ischemic stroke and AHI was detected in men (P = 0.016). In OSAH patients with AHI of 5-25, each unitary increase in AHI severity was associated with a 6% increase in stroke risk. [116] Whether OSAH contributes to causation of stroke, independently of other risk factors, remains unclear and further investigation is warranted.
CPAP therapy normalizes the blunted cerebral blood flow response to hypoxia observed in patients with OSAH and reduces carotid intima-media thickness. [117] Although early treatment of OSAH in stroke patients should, in principle, protect them from further brain damage and improve functional recovery, available data are conflicting. Observational studies have found a beneficial effect of CPAP on cardiovascular outcomes. Martínez-García et al. prospectively followed up 166 patients with ischemic stroke and AHI at least 20; those who used CPAP for at least 4 h/day had a risk of mortality and incidence of nonfatal cardiovascular events similar to that of the control group, whereas patients with OSAH who did not tolerate CPAP had an increased adjusted risk of mortality (HR 1.58, 95% CI 1.01-2.49; P = 0.04) and incident cardiovascular events (HR 2.87, 1.11-7.71; P = 0.03). [118, 119] However, these positive findings have not been replicated in a randomized trial. Parra et al. followed up 140 patients with acute first-time stroke and AHI of at least 20 who were randomized to CPAP or habitual treatment for 2 years. [120] A key point in investigating the role of CPAP in stroke is the timing of treatment, which, in most studies, did not begin during the acute phase (first 24 h) of stroke onset, but several days later. In summary, available data suggest that OSAH might be a predisposing risk factor for stroke. The role of CPAP therapy is much less clear; acceptance of the device and early treatment after the onset of a stroke might be key points for achieving better outcomes.
There is increasing evidence that adequate CPAP therapy leads to a significant reduction in cardiovascular morbidity. Recent studies of 130 elderly Japanese patients aged 65-86 years with moderate-to-severe OSAH (AHI ≥15/h) and a history of hospitalization due to CVD, analyzed by Kaplan-Meier curves indicated that event-free survival was significantly lower in the untreated OSA group than in the CPAP group (P < 0.005). A multivariate analysis showed that the risk was significantly increased in the untreated OSAH group (hazard ratio 5.13; 95% CI 1.01-42.0; P < 0.05). Moderate-to-severe OSAH not treated with CPAP.
BiPAP have been proven to be more efficacious in those with co-existing chronic obstructive pulmonary disease (COPD), and CHF. For those OSAH, CHF with associated CSA and Cheyne stokes respiration; assisted servo ventilator BIPAP is the treatment of choice. [121] conclusion For over 40 years, the relationship between OSAH and CVDs has been studied with a growing body of evidence of associated risks factors. OSAH is a common health concern caused by repeated episodes of narrowing and collapse of the upper airway during sleep. The events associated with OSAH lead to brain arousal, intrathoracic pressure changes, and intermittent episodes of hypoxemia and reoxygenation. These events activate pathways such as oxidative stress, sympathetic activation, inflammation, hypercoagulability, endothelial dysfunction, and metabolic dysregulation that predispose patients with OSAH to HTN and atherosclerosis. OSAH is a common cause of systemic HTN and should be suspected in HT individuals, especially those with resistant HTN. In patients with OSAH, CPAP treatment reduces BP, and its effects are related to compliance and baseline BP. Evidence suggests that OSAH is a risk factor for stroke and HF. An association between coronary heart disease and OSAH seems to be limited to middle-aged men (30-70 years) . Cardiac rhythm disorders occur in about half of the patients with OSAH, but their clinical relevance is still unknown. The association of OSAH with cardiovascular risk is mainly based on studies in men, and an association has yet to be established in women. Data on older patients are similarly scarce.
The treatment of OSAH should be multidisciplinary, and main objectives should include remission of symptoms and reduction of cardiovascular risk factors. To correct the predisposing or aggravating factors related to OSAH, behavioral changes should be recommended. These include avoiding alcohol, caffeine, or other stimulants of wakefulness before sleep; increased physical activity during the day; avoiding naps at unusual hours; and discontinuation of sedating drugs and obesity control. It is important to emphasize that drug therapy for OSAH treatment has not been defined yet as an effective choice as clinical studies showing benefit are limited. The gold-standard treatment of OSA is CPAP. Currently, there is not enough evidence to support treatment with CPAP for primary or secondary prevention of CVD except those patients with proven OSAH by polysomnography.
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